Evidence map›Paper›PMID 38273276›Full record

ArticleJournal of translational medicine2024

Synergistic use of anti-inflammatory ketorolac and gentamicin to target staphylococcal biofilms.

Amita Sekar, Dmitry Gil, Peyton Tierney, Madeline McCanne, Vikram Daesety, Darina Trendafilova, Orhun K Muratoglu, Ebru Oral

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Levofloxacin/ketorolac combination versus levofloxacin alone for topically treating moderate-severe acute bacterial conjunctivitis: a randomized controlled trial.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Amita SekarHarris Orthopaedic Laboratory, Massachusetts General Hospital, Boston, USA.
Dmitry GilHarris Orthopaedic Laboratory, Massachusetts General Hospital, Boston, USA.
Peyton TierneyHarris Orthopaedic Laboratory, Massachusetts General Hospital, Boston, USA.
Madeline McCanneHarris Orthopaedic Laboratory, Massachusetts General Hospital, Boston, USA.
Vikram DaesetyHarris Orthopaedic Laboratory, Massachusetts General Hospital, Boston, USA.
Darina TrendafilovaHarris Orthopaedic Laboratory, Massachusetts General Hospital, Boston, USA.
Orhun K MuratogluHarris Orthopaedic Laboratory, Massachusetts General Hospital, Boston, USA.
Ebru OralHarris Orthopaedic Laboratory, Massachusetts General Hospital, Boston, USA. eoral@mgh.harvard.edu.ORCID 0000-0001-5761-719X
Boston University · USMassachusetts General Hospital · US

Funding

Drug-eluting joint implants with synergistic antimicrobial release and risk stratified models of preclinical efficacy testingR01AR077023 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI ORAL, EBRU · 2020 to 2024
$1.8M
NIAMS NIH HHS R01 AR077023
6 · The paper itself

Abstract

backgroundWhile antibiotics remain our primary tools against microbial infection, increasing antibiotic resistance (inherent and acquired) is a major detriment to their efficacy. A practical approach to maintaining or reversing the efficacy of antibiotics is the use of other commonly used therapeutics, which show synergistic antibacterial action with antibiotics. Here, we investigated the extent of antibacterial synergy between the antibiotic gentamicin and the anti-inflammatory ketorolac regarding the dynamics of biofilm growth, the rate of acquired resistance, and the possible mechanism of synergy.

methodsControl (ATCC 12600, ATCC 35984) and clinical strains (L1101, L1116) of Staphylococcus aureus and Staphylococcus epidermidis with varying antibiotic susceptibility profiles were used in this study to simulate implant-material associated low-risk and high-risk biofilms in vitro. The synergistic action of gentamicin sulfate (GS) and ketorolac tromethamine (KT), against planktonic staphylococcal strains were determined using the fractional inhibitory concentration measurement assay. Nascent (6 h) and established (24 h) biofilms were grown on 316L stainless steel plates and the synergistic biofilm eradication activity was determined and characterized using adherent bacteria count, minimum biofilm eradication concentration (MBEC) measurement for GS, visualization by live/dead imaging, scanning electron microscopy, gene expression of biofilm-associated genes, and bacterial membrane fluidity assessment.

resultsGentamicin-ketorolac (GS-KT) combination demonstrated synergistic antibacterial action against planktonic Staphylococci. Control and clinical strains showed distinct biofilm growth dynamics and an increase in biofilm maturity was shown to confer further resistance to gentamicin for both 'low-risk' and 'high-risk' biofilms. The addition of ketorolac enhanced the antibiofilm activity of gentamicin against acquired resistance in staphylococcal biofilms. Mechanistic studies revealed that the synergistic action of gentamicin-ketorolac interferes with biofilm morphology and subverts bacterial stress response altering bacterial physiology, membrane dynamics, and biofilm properties.

conclusionThe results of this study have a significant impact on the local administration of antibiotics and other therapeutic agents commonly used in the prevention and treatment of orthopaedic infections. Further, these results warrant the study of synergy for the concurrent or sequential administration of non-antibiotic drugs for antimicrobial effect.

Indexed as

GentamicinsStaphylococcal InfectionsAnti-Bacterial AgentsBiofilmsHumansKetorolacMicrobial Sensitivity TestsStaphylococcus aureusAnti-Bacterial AgentsGentamicinsKetorolac

Identifiers

PMID38273276
PMCPMC10809490
OpenAlexW4391227083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.